Table 1.
Presentation of All 180 Patients With Severe Dengue and Separated Into Survivors and Nonsurvivors
| All (N = 180) | Survivors (n = 141) | Nonsurvivors (n = 39) | |
|---|---|---|---|
| Female | 77 (42.8)/103 (57.2)a | 56 (39.7)/85 (60.3) | 21 (53.8)/18 (46.2) |
| Splenomegaly | 7 (4.6)/144 (95.4); 29 | 4 (3.5)/109 (96.5); 28 | 3 (7.9)/35 (92.1); 1 |
| Hepatomegaly | 33 (21.9)/118 (78.1); 29 | 19 (16.8)/94 (83.2); 28 | 14 (36.8)/24 (63.2); 1 |
| Hemophagocytosis | 16 (80.0)/4 (20.0); 160 | 7 (70.0)/3 (30.0); 131 | 9 (90.0)/1 (10.0); 29 |
| Leak | 108 (60.0)/72 (40.0) | 79 (56.0)/62 (44.0) | 29 (74.4)/10 (25.6) |
| Bleed | 64 (35.6)/116 (64.4) | 41 (29.1)/100 (70.9) | 23 (59.0)/16 (41.0) |
| Severe organ involvement | 99 (56.3)/77 (43.8); 4 | 62 (45.3)/75 (54.7); 4 | 37 (94.9)/2 (5.1) |
| Severe organ involvement (liver) | 68 (38.9)/107 (61.1); 5 | 36 (26.5)/100 (73.5); 5 | 32 (82.1)/7 (17.9) |
| Severe organ involvement (CNS) | 35 (19.4)/145 (80.6) | 25 (17.7)/116 (82.3) | 10 (25.6)/29 (74.4) |
| Severe organ involvement (heart and other) | 38 (21.1)/142 (78.9) | 15 (10.6)/126 (89.4) | 23 (59.0)/16 (41.0) |
| Intubation and ventilation | 70 (38.9)/110 (61.1) | 31 (22.0)/110 (78.0) | 39 (100.0)/0 (0.0) |
| Inotropic support | 55 (30.6)/125 (69.4) | 16 (11.3)/125 (88.7) | 39 (100.0)/0 (0.0) |
| Continuous veno-venous hemodiafiltration | 32 (17.8)/148 (82.2) | 4 (2.8)/137 (97.2) | 28 (71.8)/11 (28.2) |
| Corticosteroid treatment | 25 (13.9)/155 (86.1) | 12 (8.5)/129 (91.5) | 13 (33.3)/26 (66.7) |
| Age at hospital admission, y | 34.9 (18.2–84.3)b | 34.4 (18.2–79.7) | 43.6 (19.3–84.3) |
| Length of hospitalization, d | 5.9 (0.2–60.1) | 6.1 (2.7–60.1) | 2.6 (0.2–43.7) |
| Length of ICU, d | 2.6 (0.1–60.0) | 2.7 (0.2–60.0) | 2.1 (0.1–43.3) |
| Lowest platelets, ×109/L | 15.5 (0–154) | 17 (0–154) | 9 (1–99) |
| Peak triglycerides, mmol/L | 2.33 (0.7–11.2); 117 | 2.49 (0.87–11.2); 96 | 2.065 (0.7–9.7); 21 |
| Lowest fibrinogen, g/L | 2.15 (1–5.7); 144 | 2.35 (1.3–3.8); 117 | 1.55 (1–5.7); 27 |
| Peak ferritin, μg/L | 22 236 (565 to >100 000); 104 | 20 356 (565 to >100 000); 86 | 72 000 (2420 to >100 000); 18 |
| Peak aspartate aminotransferase, U/L | 510 (22–35 427); 4 | 356 (22–9861); 4 | 4799 (113–35 427) |
| Peak alanine aminotransferase, U/L | 246 (12–8330); 1 | 181.5 (12–3344); 1 | 1892 (81–8330) |
| Peak lactate dehydrogenase, U/L | 1203 (249–21 591); 7 | 843.5 (249–9982); 7 | 6244 (492–21 591) |
| Peak creatinine, μmol/L | 100 (20–1440) | 90 (20–650) | 300 (80–1440) |
| APACHE II score | 12 (1–46); 2 | 10 (1–26) | 28 (7–46); 2 |
| SAPS II score | 20 (6–106); 2 | 17 (6–59) | 62 (9–106); 2 |
| SOFA score | 6 (0–20); 2 | 5 (0–14) | 15 (4–20); 2 |
Abbreviations: APACHE, Acute Physiology, Age, Chronic Health Evaluation; CNS, central nervous system; ICU, intensive care unit; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment.
aNo. (%) yes/no; no. missing (if applicable).
bMedian (range); no. missing (if applicable).